Latachimo Combination Adverse Reactions

Since studies which could clarify the incidence of adverse reactions have not been conducted, the incidence of adverse reactions associated with the administration of this product is unknown.
Clinically Significant Adverse Reactions (Frequency unknown): Iris pigmentation: Since iris pigmentation may occur, patients should be examined regularly. If iris pigmentation occurs, use of this product may be discontinued according to patient's clinical condition (see Important Precautions under Precautions).
Ocular pemphigoid: Ocular pemphigoid may occur. If symptoms such as conjunctival hyperemia, corneal epithelium disorder, keratoconjunctivitis sicca, conjunctival atrophy, entropion of eyelashes, or eyelid adhesion are observed, administration should be discontinued and appropriate measures should be taken.
Bronchospasm, dyspnoea and respiratory failure: Bronchospasm, dyspnoea and respiratory failure may occur. In the event of such symptoms, treatment should be discontinued and appropriate measures taken.
Cardiac block, cardiac failure, cardiac arrest, cerebral ischemia and cerebrovascular disorder: Heart block, heart failure, cardiac arrest, cerebral ischemia and cerebrovascular disorder may occur. In the event of such symptoms, treatment should be discontinued and appropriate measures taken.
Systemic lupus erythematosus: Systemic lupus erythematosus may occur. In the event of such symptoms, treatment should be discontinued and appropriate measures taken.
Other Adverse Reactions: See Table 2.

Click on icon to see table/diagram/image